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Abstract
Aberrant ovarian granulosa cell proliferation and apoptosis may lead to granulosa cell tumors (GCT), the pathogenesis of
which involves transcription factors GATA4, FOXL2, and SMAD3. FOXL2 gene harbors a point mutation (C134W) in a vast
majority of GCTs. GATA4 is abundantly expressed in GCTs and its expression correlates with poor prognosis. The TGF-b
mediator SMAD3 promotes GCT cell survival through NF-kB activation, and interacts with FOXL2. Here, we find that the
expression patterns of these factors overlap in the normal human ovary and 90 GCTs, and positively correlate with each
other and with their mutual target gene CCND2, which is a key factor for granulosa cell proliferation. We have explored the
molecular interactions of FOXL2, GATA4, and SMAD3 and their roles in the regulation of CCND2 using co-
immunoprecipitation, promoter transactivation, and cell viability assays in human GCT cells. We found that not only
SMAD3, but also GATA4 physically interact with both wild type and C134W-mutated FOXL2. GATA4 and SMAD3
synergistically induce a 8-fold increase in CCND2 promoter transactivation, which is 50% reduced by both FOXL2 types. We
confirmed that wild type FOXL2 significantly decreases cell viability. Interestingly, GATA4 and SMAD3 caused a marked
reduction of GCT cell apoptosis induced by wild type FOXL2. Thus, the effects of GATA4 and SMAD3 on both cell viability
and apoptosis are distinct from those of wild type FOXL2; a perturbation of this balance due to the oncogenic FOXL2
mutation is likely to contribute to GCT pathogenesis.
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Introduction
Granulosa cell tumors (GCTs) are sex cord stromal tumors that
represent 3–5% of all ovarian cancers, with two distinct subtypes:
the rare juvenile and the more common adult subtype [1]. The
overall prognosis is favorable compared to ovarian epithelial
cancers, but recurrences occur even decades after primary
diagnosis in up to 25–30% of patients, significantly increasing
mortality due to the disease [1–3]. GCTs are thought to arise from
normal granulosa cells of developing follicles and share features of
hormonally active granulosa cells [3]. The vast majority of adult
type GCTs bear a missense point mutation c.402C.G (codon
C134W) in the gene coding for transcription factor FOXL2 [3–5].
The unbiased whole transcriptome analyses on GCT patient
samples and cell line suggested that C134W mutated FOXL2 fails
to down-regulate genes involved in the control of cell cycle, and to
up-regulate (as wild type (wt) FOXL2 does) genes involved in cell
death [6,7]. A mechanistic explanation of the effect of C134W
mutation is however still lacking.
FOXL2 is the earliest known marker of ovarian differentiation
and a key regulator of ovarian development and function [8,9]. In
Foxl22/2 mice, the differentiation of granulosa cells is blocked at
the primordial follicle stage [9], and a conditional knockout model
demonstrated that FOXL2 permanently prevents transdifferentia-
tion of the ovarian granulosa cells into Sertoli-like cells in murine
ovaries [8]. In cell models, FOXL2 modulates the expression of
key genes in granulosa cell differentiation and steroidogenesis,
such as StAR, P450scc, P450CYP17, and aromatase [10,11].
FOXL2 also regulates cell survival and proliferation in granulosa
cell models, inhibiting cell cycle progression [12], and expression
of CCND2, a positive regulator of cell cycle progression required
for granulosa cell proliferation. Furthermore, wild-type FOXL2 is
able to induce apoptosis in granulosa cells, whereas the C134W
form is less effective, and may provide malignant granulosa cells
with a survival advantage [13,14].
Several proteins that interact with FOXL2 have been identified,
including DEAD box-containing protein DP103 and transcription
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factors such as the estrogen receptor ERa, the orphan nuclear
receptor SF-1 and SMAD3 (reviewed in [10]). Using yeast two-
hybrid screening and co-immunoprecipitation we recently identi-
fied 10 novel FOXL2 partners of which some are able to repress
FOXL2 transcriptional activity irrespective of the promoter [13].
Interestingly, CREM-t2a, which acted as a repressor on most
promoters, increased wt FOXL2 activity on two promoters
(PTGS2 and CYP19A1), but was unable to increase the activity
of the C134W mutant. The partners that increased the pro-
apoptotic capacity of wt FOXL2 failed to increase the pro-
apoptotic ability of the C134W mutant FOXL2. Furthermore, the
anti-apoptotic partners decreased apoptosis induction by both
FOXL2 versions [13].
C134W mutated FOXL2 has been shown to inhibit the activin
and GDF-9 induction of anti-proliferative follistatin, which may
lead to increased cell proliferation and tumor formation [15].
Activin and TGF-b signaling are mediated by SMAD3, an
essential regulator of CCND2 (cyclin D2) promoter [16]. SMAD3-
deficiency in mice causes growth arrest at the preantral follicle
stage and decreased granulosa cell proliferation and survival [17].
Deficiency of inhibin-a subunit, or SMAD1/5 in mice leads to the
GCT formation; in these murine GCTs SMAD3 is up-regulated
and activated (phosphorylated) [18–20], suggesting a role for
SMAD3 in GCT pathogenesis. Furthermore, genetic removal of
SMAD3 expression from inhibin-a deficient mice leads to
attenuated granulosa cell tumor progression and down-regulated
CCND2 expression [18]. In human GCT cell lines, SMAD3
drives cell viability by activating NF-kB, which in turn up-
regulates SMAD3 expression; this positive feedback loop activates
the ERK1/2 pathway leading to increased GCT cell survival [21].
SMAD3 interacts with the transcription factor GATA4 in
murine cell models [22], suggesting a role of GATA4 in the TGF-
b/activin signaling pathway. GATA4 plays a key role in normal
granulosa cell function [23,24] and GCTs [25–27]; high GATA4
immunoreactivity denotes a more aggressive human GCT with
increased recurrence risk [25]. GATA4 can be presumed to act as
an anti-apoptotic factor, by protecting human GCT cells from
apoptosis induced by e.g. TRAIL (Tumor Necrosis Factor
Apoptosis Inducing Ligand) [27], and by activating an essential
apoptosis inhibitor BCL2 in non-human cell models [26,28].
Furthermore, GATA4 also activates CCND2 in different cell
models [26,29,30].
FOXL2, GATA4, and SMAD3 expression patterns overlap in
the fetal and adult ovary [25,31–34], but whether FOXL2 and
GATA4 interact physically is unknown. We hypothesized that
these factors altogether interact and modulate GCT cell viability
through the regulation of CCND2, strongly expressed in GCTs
[26]. In current study we show that these factors interact physically
and functionally on transactivation of CCND2 promoter. Wt
FOXL2 decreased viable GCT cell number while GATA4,
SMAD3, or C134W-mutated FOXL2 did not. Moreover, GATA4
inhibits the wt FOXL2-induced apoptosis, whereas GATA4 has
no effect on the reduced capability of C134W-mutated FOXL2 to
induce apoptosis. Finally, we demonstrate a positive correlation
between the expression levels of FOXL2, GATA4, and SMAD3 in
GCTs.
Materials and Methods
Human tissue samples and the ethics statement
We utilized the previously characterized GCT tissue microarray
of quadruple core samples from 78 primary and 12 recurrent
GCTs [25]. The c.402C.G (p.C134W) FOXL2 mutation
frequency of 90% in our sample series [5] corresponds to other
published GCT series [4]. All histological diagnoses were carefully
re-evaluated and patient charts were reviewed to obtain clinical
data [2,25]. For controls, we utilized normal ovarian tissue
samples from three pre-menopausal women operated upon for
cervical cancer. All the patients were diagnosed at 1971–2003;
according to Finnish legislation no written or verbal consent was
needed from the patients for using the archive tissue samples
coupled with clinical data. This approach was approved by the
ethical committee of Helsinki University Central Hospital and the
National Supervisory Authority for Welfare and Health in Finland
as part of GCT research program.
Immunohistochemistry
GCT tissue microarray and normal ovarian samples were
stained as previously described and presented for GATA4 and
CCND2 [25,26], with following primary antibodies: a-GATA4
1:400 (sc-1237, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), a-FOXL2 1:400 (IMG-3228, Imgenex, San Diego, CA,
USA), a-SMAD3 1:400 (#51–1500, Invitrogen Corporation,
Carlsbad, CA, USA), and a-CCND2 1:1000 (sc-593; Santa Cruz
Biotechnology). The GCT stainings were classified into three
groups based on the intensity of staining: high representing
intermediary or strong intensity in 70% of the cells, intermediate
representing moderate or strong intensity in ,70% of the cells,
and low representing negative or low intensity even if detected in
100% of the cells; scoring of GATA4 staining as described (34), i.e.
high for 80–100% positive nuclei, intermediate for 20–80%
positive nuclei, and low for 0–20% positive nuclei. Two
researchers (M.A. and N.A. or A.F) independently performed
the evaluation and disagreements were resolved by a joint review.
Cell culture and plasmids
The previously established KGN cells (kindly provided by Dr.
T. Yanase, Japan [35]), derived from an adult metastatic GCT,
harbor the c.402.G mutation in FOXL2 and were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12
medium containing 10% FBS and 1% penicillin/streptomycin
[35]. Another GCT derived cell line COV434 [36], that has a wild
type FOXL2 genotype [5], and COS-7 cells (ATCC, MD, USA)
were grown in DMEM containing 10% FBS and 1% penicillin/
streptomycin. pGL3-680 bp CCND2-luciferase reporter construct
was used for promoter transactivation assay [26]. The over-
expression plasmids or the corresponding empty vectors used
were; pMT2-GATA4-V5 (V5-tag amino acid sequence
GKPIPNPLLGLDST), untagged, V5-tagged, or GFP-tagged
pcDNA3.1-FOXL2-WT, pcDNA3.1-FOXL2-C134W,
pCDNA3.1-SMAD3 and pCMV-b-Gal.
Co-immunoprecipitation and Western blotting
COS-7 or COV434 cells were lysed 48 h after transfection in
50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100
(pH 7.6) supplemented with protease inhibitors PMSF 1 mM and
Complete mini EDTA-free cocktail (Roche Diagnostics GmbH,
Mannheim, Germany) and phosphatase inhibitors (Sigma Aldrich,
St Louis, MO, USA). Clarified lysates were used for Western
blotting or immunoprecipitated using Anti-V5 Agarose Affinity
Gel (Sigma Aldrich, St Louis, MO, USA) according to instruc-
tions. Precipitated proteins were eluted in 2x-SDS sample buffer
(100 mM Tris pH 6.8, 4% SDS, 20% glycerol and 0.1%
bromophenol blue). 100 mM DTT was further added to the
samples. Eluates were separated by SDS-PAGE using NuPage Bis-
Tris 4–12% Gels (Invitrogen Corporation) and proteins were
electrotransfered onto PVDF membranes (Hybond-P, GE Health-
care, Waukesha, WI, USA). Antibodies used for detection were:
FOXL2, GATA4, and SMAD3 Interact in GCTs
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a-GATA4 1:1000 (sc-1237, Santa Cruz Biotechnology,), a-
FOXL2 1:1000 (IMG-3228, Imgenex) and a-SMAD3 1:1000
(#51–1500, Invitrogen Corporation).
Promoter transactivation assays
KGN cells were seeded 16 hours prior to transfection at a
density of 46104 cells/cm2 and transfected using the calcium-
phosphate method (Invitrogen Corporation [37]). The biological
activity of luciferase reporter construct was assessed by the Dual-
LuciferaseH Reporter Assay System (Promega, Madison, WI,
USA). Relative luciferase units represent the ratio of firefly
luciferase activity over Renilla luciferase activity in the samples.
Data is presented as mean of three independent experiments.
Cell viability and apoptosis assays
For apoptosis/cell viability assay, KGN cells were transfected
with the overexpression plasmids by electroporation using a Neon
transfection system (Invitrogen Corporation) according to the
manual using the following settings: 1400V, 20 ms, 1 pulse. The
cell viability was assayed using Cell Proliferation Reagent WST-1
kit (Roche) after 48 h in culture as instructed by manufacturer.
Caspase 3/7 activation was measured using Caspase-GloH 3/7
Assays (Promega) 24 h after transfection following the instructions.
Figure 1. FOXL2, GATA4, and SMAD3 interaction in the transcription complex. Both COS-7 and COV434 cells were transfected for 48 h. All
cell lysates were immunoprecipitated using V5 epitope. A) COS-7 cells transfected with V5 tagged GATA4, V5 or GFP tagged wild type (WT) FOXL2 or
SMAD3 overexpression vectors as indicated. B) COS-7 cells transfected with V5 tagged GATA4 and untagged wild type (WT) or C134W mutated (MUT)
FOXL2 overexpression vectors. C) COV434 cells transfected with V5 tagged GATA4, GFP tagged wild type FOXL2 or SMAD3 overexpression vectors. D)
COV434 cells transfected with V5 tagged GATA4, SMAD3 and wild type or C134W mutated FOXL2 overexpression vectors. Immunoprecipitated
proteins were detected using antibodies against FOXL2, SMAD3 and GATA4. Total proteins are shown as controls for transfections and were detected
using antibodies against FOXL2, GATA4 and SMAD3. Similar results were obtained in at least three independent experiments.
doi:10.1371/journal.pone.0085545.g001
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Data analysis
The immunohistochemical expression data was analyzed with
Contingency tabling (262) and chi-square or Fisher’s exact tests.
Cox proportional hazards model was used according to the
methodology. The cell culture data was analyzed with oneway
ANOVA. The analyses were carried out with JMPH 7.0.1 (SAS
Institute Inc., Cary, NC, USA) software; P,0.05 was considered
significant. The data represents the means of values obtained from
3 to 6 biologically independent replicates 6 SEM.
Results
FOXL2, GATA4, and SMAD3 physically interact with each
other
Whereas FOXL2 and GATA4 have previously been shown to
co-immunoprecipitate with SMAD3 [15,22,38], the interaction of
GATA4 and FOXL2 remains unaddressed. To investigate the
interactions between FOXL2, GATA4, and SMAD3, we
transiently overexpressed V5-tagged GATA4 with SMAD3 and
either untagged, V5- or GFP-tagged wt FOXL2 in COS-7 and
COV434 cells. Unfortunately, IP experiments were unsuccessful in
KGN cells probably due to the low endogenous expression of
GATA4, FOXL2 and SMAD3 and poor transfectability. In
addition, KGN cells express both wt and mutant FOXL2 protein,
which had not allowed testing of interactions of these two variant
proteins and other factors. Protein complexes were immunopre-
cipitated using the V5 epitope. Both wt FOXL2 and SMAD3 co-
immunoprecipitated with GATA4 when overexpressed either
separately or simultaneously in both cell lines (Figure 1 A and C).
To explore the effect of FOXL2 C134W mutation on the
interactions between these transcription factors, we next over-
expressed V5-tagged GATA4 and SMAD3 with wt and C134W-
FOXL2 in COS-7 and COV434 cells. Like wt FOXL2, the
C134W-mutated form also co-immunoprecipitated with GATA4
and SMAD3 in both cell lines (Figure 1B and D), showing that a
drastic loss of interaction with these factors is not the cause of
GCT. Conversely, mutant FOXL2 appears more strongly
associated to GATA4 than wt FOXL2 in COV434 cells. Such
difference does not appear in COS-7 cells, suggesting that cell type
dependent factors may induce a stronger association of C134W
FOXL2 to GATA4. Interestingly, the expression of FOXL2 was
much stronger in COV434 cells when GATA4 was co-expressed,
suggesting that GATA4 may help in stabilizing FOXL2. However,
the actual binding affinities cannot be defined based on the
immunoprecipitation and western blot analyses.
GATA4 and SMAD3 synergistically activate CCND2
promoter, and FOXL2 attenuates the CCND2 promoter
activation
GATA4 and SMAD3 expression levels have been shown to
correlate with that of CCND2 in GCTs (this study and [26]), and
GATA4 and SMAD3 are known to activate CCND2 promoter
[16,26]. Herein, we overexpressed wt and mutated FOXL2,
GATA4, and SMAD3 in KGN cells, and measured CCND2
promoter activity. The KGN cells express both the C134W-
mutated and wt FOXL2 [5], and GATA4 and SMAD3
endogenously. SMAD3 and GATA4 together synergistically
increased the CCND2 promoter activity by 8-fold compared to
control (Figure 2). Both FOXL2 forms attenuated the SMAD3/
GATA4-induced promoter activity by approximately 50%
(Figure 2). In COS-7 cells, both FOXL2 forms also significantly
reduced GATA4-induced CCND2 promoter activity (data not
shown).
Effects of FOXL2, GATA4, and SMAD3 on cell viability and
apoptosis in GCT cells
Given the effects of GATA4, SMAD3, and both FOXL2 types
on the CCND2 promoter, we next analyzed the effect of these
factors on cell viability by overexpressing them in KGN cells using
WST-1 cell viability assay 48 h after transfection. Wt FOXL2
overexpression alone or together with GATA4 and/or SMAD3
significantly reduced the cell viability compared to control, while
overexpression of the mutated FOXL2 alone or together with
GATA4 and/or SMAD3 had no significant effect on the relative
cell number (Figure 3A). Mutated FOXL2 had distinct effects on
cell viability compared to wt FOXL2 when overexpressed with
GATA4 and SMAD3.
GATA4 has been shown to inhibit apoptosis [27], whereas
FOXL2 has been shown to induce apoptosis [13,14]. To study
whether GATA4 and/or SMAD3 modulate the FOXL2 induced
apoptosis, KGN cells were transfected with wt and C134W
versions of FOXL2, GATA4, and SMAD3 overexpression vectors,
and activation of caspase3/7 was measured as an indicator of
apoptotic activity 24 h after transfection (Figure 3B). Similarly to
previous findings [13,14], wt FOXL2 induced a 3-fold increase in
caspase 3/7 activity (p =,0.0001), whereas C134W mutated
FOXL2 showed significantly weaker effect (p =,0.0001). Over-
expression of GATA4 or SMAD3 alone or together had no effect
on caspase3/7 activity. GATA4, but not SMAD3, significantly
reduced wild type FOXL2-induced apoptosis (p = 0.0194), but had
no significant effect on C134W FOXL2-induced caspase 3/7
activation (Figure 3B).
FOXL2, GATA4, and SMAD3 have overlapping expression
patterns with each other and with CCND2 in GCTs
Finally, we analyzed the spatiotemporal protein expression
patterns of FOXL2, GATA4, and SMAD3 in normal ovaries and
Figure 2. Transactivation of CCND2 promoter is regulated by
FOXL2, GATA4, and SMAD3. Relative luciferase activity was
measured in KGN cells after transfection with CCND2 luciferase
promoter construct together with wild type or C134W-mutated FOXL2
in the presence or absence of GATA4 and SMAD3 over-expression.
CCND2 promoter activity was measured 24 h after transfection; at least
three independent experiments were performed in triplicate. Bars not
connected by the same letter are significantly different. P,0.05.
doi:10.1371/journal.pone.0085545.g002
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in a tissue microarray containing 90 GCT samples. Granulosa
cells of proliferating follicles from primary stage to large antral
ovulatory follicles demonstrated nuclear expression of transcrip-
tion factors FOXL2, GATA4, and SMAD3 (Figure 4A–F);
SMAD3 protein was also present in the cytoplasm. Previously,
we have shown that CCND2 is similarly expressed in normal
granulosa cells of primary and antral follicles as well as in GCTs
[26]; expression patterns, representative images, and scoring
results for GATA4 and CCND2 have been previously published
[25,26]. For all these four factors the staining intensities of GCTs
were classified into low-, intermediate- and high-level groups. The
majority of GCTs expressed high or intermediate levels of
FOXL2, GATA4, SMAD3 (Figure 4G–L, Table 1), and CCND2
(Table 1). The high expression patterns between the four factors
overlapped, which lends credence to their physical interactions
demonstrated above (Table 2); in short, FOXL2 and GATA4
protein expression patterns positively correlated with each other
and with that of SMAD3. GATA4 and SMAD3, but not FOXL2
correlated with CCND2.
The protein expression patterns of these four factors did not
correlate with any analyzed clinicopathological parameters of the
primary tumors, i.e., age and menopause status of the patient at
diagnosis, clinical stage, size of the tumor, tumor subtype, nuclear
atypia, and mitotic index [2,25]. In subgroup analyses of larger
and more aggressive GCTs, however, the interrelations of
FOXL2/GATA4/SMAD3 expressions were altered. The positive
correlations of FOXL2 and GATA4 with each other and with
SMAD3 were lost in tumors over 10 cm in diameter (n = 35)
(p.0.05), and the positive correlation between FOXL2 and
GATA4 was absent in the primary GCTs that had recurred
(n= 19) (p.0.05). Nevertheless, in Cox proportional hazards
model, high FOXL2 associated with an increased 5 years risk of
recurrence (RR 8.7, 95%CI 1.4–167.0, p = 0.018) and low
FOXL2 expression with low risk for tumor recurrence in 5 years
(RR 0.12, 95%CI 0.006–0.71, p = 0.018).
Discussion
The ability of tumor cells to evade apoptosis and to proliferate
excessively is a general property of cancer. FOXL2 is a potential
activator of granulosa cell apoptosis [14], as well as an inhibitor of
the cell cycle [12]. The balanced regulation of granulosa cell
proliferation and apoptosis is perturbed by the FOXL2 C134W
mutation [3], that fails to down-regulate genes involved in the
control of cell cycle and to up-regulate genes involved in apoptosis
[6,7]. In contrast, GATA4 functions as an antiapoptotic factor in
GCT cell models and high GATA4 expression in GCTs is
associated with aggressive disease [25–27]. Moreover, SMAD3
positively regulate the GCT cell proliferation by e.g. activating the
ERK1/2 signaling pathway [17,21]. The spatiotemporal expres-
sion patterns of FOXL2, GATA4, and SMAD3 coincide within
the somatic cells of the fetal and adult ovary and we now find that
human GCTs typically co-express FOXL2, GATA4, and
SMAD3.
Based on previous and present data, we hypothesized that
FOXL2, GATA4, and SMAD3 physically interact. Coherently,
co-immunoprecipitation data show the previously unknown
binding of GATA4 to FOXL2, and that SMAD3 interacts with
both GATA4 and FOXL2. The immunoprecipitation data do not
provide direct evidence that the three transcription factors are part
of the same macromolecular transcription complex but rather
proves that they have binary physical interactions with each other,
congruent with their co-expression in both normal granulosa cells
and GCTs. It is conceivable that the presence of FOXL2 disrupts
the interaction between GATA4 and SMAD3 and therefore their
synergistic regulation of key target promoters. Altogether, the lack
of positive expression correlations of FOXL2 and GATA4 in the
more aggressive GCTs suggests that imbalances in FOXL2-
GATA4-SMAD3 expression might increase the growth potential
of GCTs, leading to a more aggressive tumor behavior. The results
are also coherent with previous findings on high GATA4 or
FOXL2 expression in the primary tumor associated with risk of
recurrence [25,39].
The mouse Ccnd2 promoter harbors GATA4 binding sites, and
GATA4 binding to the Ccnd2 promoter is required for murine
cardiomyocyte proliferation [30]. GATA4 activates Ccnd2 in
Figure 3. Wt FOXL2 reduces viable cell number, and GATA4
protects GCT cells from wt FOXL2 induced apoptosis. KGN cells
were transfected with wild type FOXL2, C134W mutated FOXL2, GATA4,
and SMAD3 expression plasmids. A) The cell viability was measured
48 h after transfection. B) The activated caspase 3/7 was measured 24 h
after transfection. Viable cell number and Caspase 3/7 activity are
presented relative to control transfection as the mean 6 SEM of at least
three independent experiments performed in triplicate. Bars not
connected by the same letter are significantly different. P,0.05.
doi:10.1371/journal.pone.0085545.g003
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murine GCT cells in transactivation assays [26], whereas FOXL2
has been shown to repress CCND2 promoter, which contains
several consensus binding sites for the family of forkhead
transcription factors 59-[(G/A)(T/C)(C/A)AA(C/T)A]-39. In
KGN cells, neither FOXL2, GATA4, nor SMAD3 over-
expression alone could significantly enhance CCND2 promoter
activity, whereas simultaneous over-expression of GATA4 and
Figure 4. FOXL2, GATA4, and SMAD3 proteins are expressed in normal follicles and GCTs. Proliferating granulosa cells of primary (A–C)
and antral (D–F) follicles express high levels of the transcription factors FOXL2, GATA4 and SMAD3. For GCTs, High- (G–I) and intermediate-level (J–L)
expressing examples are shown. FOXL2 and GATA4 expression localized into the nucleus, while low levels of SMAD3 expression was also detected in
the cytoplasm. Higher magnifications are shown in insets. Scale bar = 100 mm.
doi:10.1371/journal.pone.0085545.g004
Table 1. Protein expression patterns in 78 primary and 12
recurrent granulosa cell tumors.
Staining intensities n (%)
GATA41 FOXL2 SMAD3 CCND21
High 39 (43%) 33 (37%) 36 (41%) 36 (40%)
Intermediate 42 (47%) 52 (58%) 43 (50%) 39 (43%)
Low 9 (10%) 5 (5%) 8 (9%) 15 (17%)
Total 90 90 87 90
1Expression data for the primary GCTs has been previously reported for GATA4
[25], and for CCND2 [26].
doi:10.1371/journal.pone.0085545.t001
Table 2. Correlation of protein expression patterns in 78
primary and 12 recurrent granulosa cell tumors.
Staining correlations1
GATA4 FOXL2 SMAD3 CCND2
GATA4 + (0.0031) + (0.0003) + (,0.0001)
FOXL2 + (0.0031) + (0.0119) ns
SMAD3 + (0.0003) + (0.0119) + (0.0241)
CCND2 + (,0.0001) ns + (0.0241)
1Intermediate and low staining were grouped together in the analysis; +
indicates positive correlation with p,0.05 (p values presented), ns = not
significant, blank = same antigen.
doi:10.1371/journal.pone.0085545.t002
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SMAD3 induced a synergistic activation of the promoter.
Attenuation of the promoter activation by both wt and C134W-
mutated FOXL2 suggests, along with the immunoprecipitation
data, that failure in the FOXL2-GATA4-SMAD3 physical and/or
functional interactions with CCND2 promoter cannot fully explain
how the FOXL2-C134W mutation contributes to GCT patho-
genesis. In rat granulosa cells, activation of Ccnd2 promoter
requires FSH-induced release of FOXO1 from the promoter and
positive signals from activin-SMAD2/3 pathway; consensus
SMAD3 response elements 59-[CAGACA]-39 have been identified
on the rat Ccnd2 promoter. Our findings suggest that these signals
involve GATA4/SMAD3 synergy, supporting the role of GATA4
in the proliferative TGF-b/activin signaling in granulosa cells
[22]. Given the positively correlated protein expression patterns of
GATA4-SMAD3-CCND2 in GCTs, the data suggest that
GATA4-SMAD3 co-operation is essential for CCND2 expression
and sustained proliferation of malignant granulosa cells.
Previously, endogenous GATA4 has been shown to inhibit
apoptosis in GCT cells, while the dominant negative form of
GATA4 induced basal apoptosis [27]. Wild type and the C134W-
mutated FOXL2 have differential abilities to induce apoptosis
[13,14], and we now demonstrate that GATA4 is able to protect
KGN cells from wt FOXL2-induced apoptosis in overexpression
conditions, further supporting the anti-apoptotic role of GATA4.
Our cell viability assay showed that wild type FOXL2 significantly
attenuated the GCT cell viability, while mutated FOXL2 lacked
this ability. This is in line with our previous data demonstrating
that mutated FOXL2 fails to interact with some of its pro-
apoptotic partner which promotes cell viability [13], altogether
indicating that mutation in FOXL2 gene gives the GCT cells a
growth advantage, probably not directly through CCND2
regulation but by decreasing sensitivity to apoptosis.
In conclusion, we demonstrate a previously unknown interac-
tion between FOXL2 and GATA4, together with SMAD3, and
these transcription factors can modulate the promoter activity of
the key target genes involved in GCT cell proliferation and
survival, such as CCND2. Moreover, the data further strengthens
the role of SMAD3 in human GCT pathogenesis, as previously
suggested by studies in GCT mouse models and human GCT cell
line. GATA4 and SMAD3 exhibit distinct effects compared to
wild type FOXL2 in the regulation of cell survival, whereas these
factors do not modulate decreased ability of C134W-FOXL2 to
induce apoptosis. This links GATA4 and SMAD3 into the
balanced regulation of granulosa cell viability and apoptosis, which
is abrogated by C134W-mutated FOXL2 in the GCTs.
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